Results 1 to 10 of about 259,924 (358)
A Comparison of xylazine/ketamine, diazepam/ketamine and acepromazine/ketamine anaesthesia in Rabbit [PDF]
Sokoto Journal of Veterinary Sciences, 2015 The efficacy and safety of the recommended intramuscular (im) clinical doses of xylazine-ketamine (5mg-35mg/kg), diazepam-ketamine (5mg-60mg/kg) and acepromazine-ketamine (5mg-75mg/kg) post administration were obtained, evaluated and compared using the ...
Oguntoye, CO, Oke, BO
core +4 more sources
Functional activity and connectivity signatures of ketamine and lamotrigine during negative emotional processing: a double-blind randomized controlled fMRI study [PDF]
Translational PsychiatryKetamine is a highly effective antidepressant (AD) that targets the glutamatergic system and exerts profound effects on brain circuits during negative emotional processing.
Marvin S. Meiering +10 more
doaj +2 more sources
Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses
Frontiers in Psychiatry, 2023 Ketamine-assisted psychotherapy is a promising new treatment for a variety of mental disorders of adolescence. There is currently an adolescent mental health crisis, with a high prevalence of disorders, diagnostic complexity, and many adolescents failing
Philip E. Wolfson +7 more
doaj +1 more source
International Review of Psychiatry, 2021 Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects within hours of administration.
James M. Stone +3 more
openaire +3 more sources
Frontiers in Psychiatry, 2021 Background: Craving is considered a hallmark of substance use disorder and is one of the criteria of substance use disorder. The Desires for Drug Questionnaire (DDQ) is a widely used questionnaire to assess craving for heroin. This study aimed to examine
Peng-Wei Wang +10 more
doaj +1 more source
BJPsych Open, 2023 Background The evidence base for racemic ketamine treatment for treatment-resistant major depressive disorder (TRD) continues to expand, but there are major challenges translating this evidence base into routine clinical care.
Ben Beaglehole +3 more
doaj +1 more source
NMDA Receptor Glycine Binding Site Modulators for Prevention and Treatment of Ketamine Use Disorder
Pharmaceuticals, 2023 Ketamine offers a fast-acting approach to relieving treatment-resistant depression, but its abuse potential is an issue of concern. As ketamine is a noncompetitive N-methyl-D-aspartate receptor (NMDAR) ion channel blocker, modulation of NMDAR might be an
Yu-Chin Hsiao +3 more
doaj +1 more source
Frontiers in Psychiatry, 2021 Ketamine is a glutamate N-methyl D-aspartate receptor antagonist and an anaesthetic agent that has been effectively used to treat depression. However, ketamine has also been increasingly used for recreational purposes.
Linying Liu +8 more
doaj +1 more source